{ "run": { "id": "cmnr14ufp05rsp658ufjjfuly", "region": "US", "assetId": "cmnr14uez05rop658mxjntqpy", "ticker": "PM", "snapshotId": "cmnr14ufc05rqp658rmefw7uk", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:36.275Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr14ufc05rqp658rmefw7uk", "assetId": "cmnr14uez05rop658mxjntqpy", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 160.94, "dayLow": 155.139, "volume": 4145073, "dayHigh": 161.18, "currency": "USD", "prevClose": 157.49, "week52Low": 142.11, "week52High": 191.3 }, "fundamentals": { "pe": 22.0632737276479, "beta": 0.330441177886008, "epsTTM": 7.27, "fcfTTM": 7794000000, "growth": { "epsYoy": 0.6048565121412802, "revenueYoy": 0.07312952109403875 }, "sector": "Cigarettes", "margins": { "net": 0.279177327297776, "gross": 0.6711769336744735, "operating": 0.366364888801417 }, "website": "http://pmi.com", "industry": "Tobacco", "pegRatio": 0.364768722577536, "ebitdaTTM": 18783000000, "forwardPe": 19.2326139088729, "marketCap": 283000000000, "totalCash": 4872000000, "totalDebt": 45302000000, "debtEquity": -4.53291975185111, "quickRatio": 0.6517481417390962, "revenueTTM": 40648000000, "companyName": "Philip Morris International Inc.", "priceToBook": -31.0889885401096, "currentRatio": 0.9581547174263578, "dividendYield": 0.0353270102379014, "returnOnAssets": 0.1640239936402399, "returnOnEquity": -1.13548128877326, "analystOpinions": null, "businessSummary": "Philip Morris International Inc. (PMI) is a tobacco company, with products sold in over 180 countries. Marlboro is PMI’s most recognized brand, but in the last quarter of 2023, Iqos generated the greatest revenue. Philip Morris International is often referred to as one of the companies comprising Big Tobacco. The company ranked No. 121 in the 2025 Fortune 500 list of the largest US corporations by total revenue.", "enterpriseValue": 290012400000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 83100, "sharesOutstanding": 1556679579, "enterpriseToEbitda": 15.44015333013895, "analystTargetMedian": null, "enterpriseToRevenue": 7.134727415863019, "operatingCashflowTTM": 12233000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:36.264Z" }, "results": [ { "id": "cmnr14ufr05rup658qbcl5bz2", "runId": "cmnr14ufp05rsp658ufjjfuly", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"PM\",\"currency\":\"USD\",\"current_price\":160.94,\"target_price_6m\":172,\"target_price_12m\":181,\"recommendation\":\"BUY\",\"confidence\":0.67,\"thesis_bullets\":[\"IQOS and ZYN smoke-free products drive durable mid-single-digit revenue growth\",\"Operating margin expansion from higher-margin reduced-risk products mix shift\",\"Attractive PEG ratio of 0.36 signals growth undervalued relative to earnings momentum\",\"Strong FCF generation (~$7.8B TTM) supports 3.5% dividend and debt reduction\",\"Defensive low-beta profile (0.33) offers resilience in volatile macro environment\"],\"key_drivers\":[{\"driver\":\"IQOS heated tobacco unit volume growth globally\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"ZYN nicotine pouch rapid US and international expansion\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Pricing power in combustible tobacco portfolio\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Mix shift toward higher-margin smoke-free products\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"US IQOS re-launch potential (ITC patent resolution)\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Elevated net debt (~$40B) limiting financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Currency headwinds from strong USD on international revenues\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory tightening on nicotine/tobacco products globally\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Regulatory bans or restrictions on heated tobacco or nicotine pouches in key markets\",\"FX translation risk given >95% international revenue base\",\"High leverage with negative book equity constrains capital allocation flexibility\",\"Competitive threats from BAT, JTI, and emerging nicotine alternatives\",\"Potential US FDA marketing denial orders for IQOS or ZYN variants\",\"Slower-than-expected consumer switching from cigarettes to smoke-free products\"],\"assumptions\":{\"revenue_cagr_3y\":0.075,\"ebit_margin_target\":0.39,\"wacc\":0.08,\"terminal_multiple\":20},\"scenarios\":{\"bear\":{\"target_price\":140,\"prob\":0.2,\"notes\":\"Regulatory setbacks or IQOS growth stalls; multiple compresses to ~17x forward EPS.\"},\"base\":{\"target_price\":181,\"prob\":0.55,\"notes\":\"Continued smoke-free momentum; EPS ~$9.10 at ~20x forward P/E.\"},\"bull\":{\"target_price\":210,\"prob\":0.25,\"notes\":\"Accelerated IQOS/ZYN adoption plus US re-launch; multiple expands to ~22x.\"}},\"method_notes\":\"Valuation anchored on forward P/E applied to projected FY EPS (~$9.00-9.50). Forward P/E of ~20x reflects smoke-free growth premium vs tobacco peers (~14-16x). Revenue CAGR of 7.5% driven by IQOS/ZYN volume + pricing. EBIT margin expansion from 36.6% to ~39% from RRP mix. PEG of 0.36 supports undervaluation thesis. 12M expected return ~12.5% justifies BUY. Probability-weighted scenario value ~$179 aligns with base. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Regulatory bans or restrictions on heated tobacco or nicotine pouches in key markets", "FX translation risk given >95% international revenue base", "High leverage with negative book equity constrains capital allocation flexibility", "Competitive threats from BAT, JTI, and emerging nicotine alternatives", "Potential US FDA marketing denial orders for IQOS or ZYN variants", "Slower-than-expected consumer switching from cigarettes to smoke-free products" ], "ticker": "PM", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Continued smoke-free momentum; EPS ~$9.10 at ~20x forward P/E.", "target_price": 181 }, "bear": { "prob": 0.2, "notes": "Regulatory setbacks or IQOS growth stalls; multiple compresses to ~17x forward EPS.", "target_price": 140 }, "bull": { "prob": 0.25, "notes": "Accelerated IQOS/ZYN adoption plus US re-launch; multiple expands to ~22x.", "target_price": 210 } }, "confidence": 0.67, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.075, "terminal_multiple": 20, "ebit_margin_target": 0.39 }, "key_drivers": [ { "driver": "IQOS heated tobacco unit volume growth globally", "impact": "HIGH", "direction": "POS" }, { "driver": "ZYN nicotine pouch rapid US and international expansion", "impact": "HIGH", "direction": "POS" }, { "driver": "Pricing power in combustible tobacco portfolio", "impact": "MED", "direction": "POS" }, { "driver": "Mix shift toward higher-margin smoke-free products", "impact": "HIGH", "direction": "POS" }, { "driver": "US IQOS re-launch potential (ITC patent resolution)", "impact": "MED", "direction": "POS" }, { "driver": "Elevated net debt (~$40B) limiting financial flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Currency headwinds from strong USD on international revenues", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory tightening on nicotine/tobacco products globally", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation anchored on forward P/E applied to projected FY EPS (~$9.00-9.50). Forward P/E of ~20x reflects smoke-free growth premium vs tobacco peers (~14-16x). Revenue CAGR of 7.5% driven by IQOS/ZYN volume + pricing. EBIT margin expansion from 36.6% to ~39% from RRP mix. PEG of 0.36 supports undervaluation thesis. 12M expected return ~12.5% justifies BUY. Probability-weighted scenario value ~$179 aligns with base. Not investment advice.", "current_price": 160.94, "recommendation": "BUY", "thesis_bullets": [ "IQOS and ZYN smoke-free products drive durable mid-single-digit revenue growth", "Operating margin expansion from higher-margin reduced-risk products mix shift", "Attractive PEG ratio of 0.36 signals growth undervalued relative to earnings momentum", "Strong FCF generation (~$7.8B TTM) supports 3.5% dividend and debt reduction", "Defensive low-beta profile (0.33) offers resilience in volatile macro environment" ], "target_price_6m": 172, "target_price_12m": 181 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 35187, "createdAt": "2026-04-09T05:21:36.275Z", "usage": { "inputTokens": 3611, "outputTokens": 1639, "costUsd": 0.05903 } }, { "id": "cmnr14ufr05rxp6583ldb9z3p", "runId": "cmnr14ufp05rsp658ufjjfuly", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearchAI\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"PM\",\n \"currency\": \"USD\",\n \"current_price\": 160.94,\n \"target_price_6m\": 155.0,\n \"target_price_12m\": 137.4,\n \"recommendation\": \"SELL\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\"Transition to reduced-risk products supports modest growth.\", \"High operating margins ensure stable cash flow generation.\", \"Regulatory pressures and declining volumes pose significant risks.\", \"Current valuation is stretched relative to earnings growth.\", \"Dividend yield offers limited downside protection.\"],\n \"key_drivers\": [\n { \"driver\": \"IQOS adoption rate\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory changes\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Currency fluctuations\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Cost management efficiency\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt levels and leverage\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Dividend sustainability\", \"impact\": \"LOW\", \"direction\": \"POS\" },\n { \"driver\": \"Market share in emerging markets\", \"impact\": \"HIGH\", \"direction\": \"POS\" }\n ],\n \"risks\": [\"Increased global tobacco regulations and taxes\", \"Litigation and health-related lawsuits\", \"Slow adoption of reduced-risk products\", \"Economic downturn affecting consumer spending\", \"Foreign exchange volatility\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.35,\n \"wacc\": 0.07,\n \"terminal_multiple\": 18\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 114.5, \"prob\": 0.3, \"notes\": \"Severe regulatory headwinds and volume decline.\" },\n \"base\": { \"target_price\": 137.4, \"prob\": 0.5, \"notes\": \"Moderate growth with stable margins.\" },\n \"bull\": { \"target_price\": 152.67, \"prob\": 0.2, \"notes\": \"Strong IQOS adoption and multiple expansion.\" }\n },\n \"method_notes\": \"Valuation based on forward EPS and peer multiples. SELL due to high current price relative to growth. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "EquityResearchAI", "risks": [ "Increased global tobacco regulations and taxes", "Litigation and health-related lawsuits", "Slow adoption of reduced-risk products", "Economic downturn affecting consumer spending", "Foreign exchange volatility" ], "ticker": "PM", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate growth with stable margins.", "target_price": 137.4 }, "bear": { "prob": 0.3, "notes": "Severe regulatory headwinds and volume decline.", "target_price": 114.5 }, "bull": { "prob": 0.2, "notes": "Strong IQOS adoption and multiple expansion.", "target_price": 152.67 } }, "confidence": 0.6, "assumptions": { "wacc": 0.07, "revenue_cagr_3y": 0.05, "terminal_multiple": 18, "ebit_margin_target": 0.35 }, "key_drivers": [ { "driver": "IQOS adoption rate", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Currency fluctuations", "impact": "MED", "direction": "NEG" }, { "driver": "Cost management efficiency", "impact": "MED", "direction": "POS" }, { "driver": "Debt levels and leverage", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend sustainability", "impact": "LOW", "direction": "POS" }, { "driver": "Market share in emerging markets", "impact": "HIGH", "direction": "POS" } ], "method_notes": "Valuation based on forward EPS and peer multiples. SELL due to high current price relative to growth. Not investment advice.", "current_price": 160.94, "recommendation": "SELL", "thesis_bullets": [ "Transition to reduced-risk products supports modest growth.", "High operating margins ensure stable cash flow generation.", "Regulatory pressures and declining volumes pose significant risks.", "Current valuation is stretched relative to earnings growth.", "Dividend yield offers limited downside protection." ], "target_price_6m": 155, "target_price_12m": 137.4 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 348, "createdAt": "2026-04-09T05:21:36.275Z", "usage": { "inputTokens": 2127, "outputTokens": 4111, "costUsd": 0.002322 } }, { "id": "cmnr14ufr05rvp6586mo2xdqv", "runId": "cmnr14ufp05rsp658ufjjfuly", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_PM_v1\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"PM\",\n \"currency\": \"USD\",\n \"current_price\": 160.94,\n \"target_price_6m\": 170.0,\n \"target_price_12m\": 180.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.8,\n \"thesis_bullets\": [\n \"Smoke-free products like IQOS and ZYN now drive the majority of revenue and margin expansion.\",\n \"Strong pricing power in legacy combustibles effectively offsets secular volume declines across global markets.\",\n \"ZYN's rapid US market penetration provides a highly profitable, fast-growing revenue stream.\",\n \"Robust free cash flow generation of $7.8B secures the attractive 3.5% dividend yield.\",\n \"Forward P/E of 19.2x is justified by industry-leading transition to reduced-risk tobacco products.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"IQOS user acquisition\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"ZYN US volume growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Combustible pricing variance\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Combustible volume declines\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Foreign exchange fluctuations\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory actions on flavors\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Debt reduction progress\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"FDA or global regulatory crackdowns on flavored oral nicotine (ZYN) or heated tobacco.\",\n \"Faster-than-expected decline in legacy combustible cigarette volumes impacting near-term cash flows.\",\n \"Adverse foreign exchange movements negatively impacting USD-reported earnings.\",\n \"Increased excise taxes on smoke-free products compressing future operating margins.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.065,\n \"ebit_margin_target\": 0.38,\n \"wacc\": 0.075,\n \"terminal_multiple\": 16.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 140.0,\n \"prob\": 0.2,\n \"notes\": \"Regulatory bans on ZYN flavors and accelerated combustible declines compress valuation multiples.\"\n },\n \"base\": {\n \"target_price\": 180.0,\n \"prob\": 0.6,\n \"notes\": \"Continued IQOS/ZYN momentum and steady combustible pricing drive mid-single-digit earnings growth.\"\n },\n \"bull\": {\n \"target_price\": 200.0,\n \"prob\": 0.2,\n \"notes\": \"Faster US IQOS rollout and ZYN international expansion drive significant multiple expansion.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF (7.5% WACC, 2% terminal growth) and 18x NTM P/E. The ~12% upside to the 12M target supports a BUY rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "EquityResearch_PM_v1", "risks": [ "FDA or global regulatory crackdowns on flavored oral nicotine (ZYN) or heated tobacco.", "Faster-than-expected decline in legacy combustible cigarette volumes impacting near-term cash flows.", "Adverse foreign exchange movements negatively impacting USD-reported earnings.", "Increased excise taxes on smoke-free products compressing future operating margins." ], "ticker": "PM", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Continued IQOS/ZYN momentum and steady combustible pricing drive mid-single-digit earnings growth.", "target_price": 180 }, "bear": { "prob": 0.2, "notes": "Regulatory bans on ZYN flavors and accelerated combustible declines compress valuation multiples.", "target_price": 140 }, "bull": { "prob": 0.2, "notes": "Faster US IQOS rollout and ZYN international expansion drive significant multiple expansion.", "target_price": 200 } }, "confidence": 0.8, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.065, "terminal_multiple": 16, "ebit_margin_target": 0.38 }, "key_drivers": [ { "driver": "IQOS user acquisition", "impact": "HIGH", "direction": "POS" }, { "driver": "ZYN US volume growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Combustible pricing variance", "impact": "MED", "direction": "POS" }, { "driver": "Combustible volume declines", "impact": "MED", "direction": "NEG" }, { "driver": "Foreign exchange fluctuations", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory actions on flavors", "impact": "HIGH", "direction": "NEG" }, { "driver": "Debt reduction progress", "impact": "LOW", "direction": "POS" } ], "method_notes": "Valuation based on a 10-year DCF (7.5% WACC, 2% terminal growth) and 18x NTM P/E. The ~12% upside to the 12M target supports a BUY rating. Not investment advice.", "current_price": 160.94, "recommendation": "BUY", "thesis_bullets": [ "Smoke-free products like IQOS and ZYN now drive the majority of revenue and margin expansion.", "Strong pricing power in legacy combustibles effectively offsets secular volume declines across global markets.", "ZYN's rapid US market penetration provides a highly profitable, fast-growing revenue stream.", "Robust free cash flow generation of $7.8B secures the attractive 3.5% dividend yield.", "Forward P/E of 19.2x is justified by industry-leading transition to reduced-risk tobacco products." ], "target_price_6m": 170, "target_price_12m": 180 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 21083, "createdAt": "2026-04-09T05:21:36.275Z", "usage": { "inputTokens": 2500, "outputTokens": 898, "costUsd": 0.015776 } }, { "id": "cmnr14ufr05rtp658vkf3nftw", "runId": "cmnr14ufp05rsp658ufjjfuly", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"PM\",\"currency\":\"USD\",\"current_price\":160.94,\"target_price_6m\":168.5,\"target_price_12m\":173,\"recommendation\":\"BUY\",\"confidence\":0.64,\"thesis_bullets\":[\"Smoke-free mix supports above-sector revenue growth and a justified premium multiple.\",\"IQOS and oral nicotine can offset secular combustible volume declines.\",\"High margins and cash flow support dividends, buybacks flexibility, and deleveraging.\",\"Current valuation is full for tobacco, limiting upside if growth normalizes.\",\"Regulatory, litigation, and currency risks remain material despite defensive demand.\"],\"key_drivers\":[{\"driver\":\"IQOS adoption\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Oral nicotine growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Combustible pricing\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Cigarette volume declines\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Smoke-free margin mix\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"FX translation\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Debt reduction\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Regulation and excise\",\"impact\":\"HIGH\",\"direction\":\"NEG\"}],\"risks\":[\"Nicotine regulation or flavor restrictions\",\"Slower IQOS or oral nicotine adoption\",\"FX volatility across international markets\",\"Litigation or tax escalation\",\"Higher rates prolong leverage concerns\"],\"assumptions\":{\"revenue_cagr_3y\":0.055,\"ebit_margin_target\":0.38,\"wacc\":0.075,\"terminal_multiple\":19.5},\"scenarios\":{\"bear\":{\"target_price\":142,\"prob\":0.25,\"notes\":\"Growth slows and regulation or FX compresses the valuation multiple.\"},\"base\":{\"target_price\":173,\"prob\":0.5,\"notes\":\"Smoke-free growth offsets combustibles and sustains a premium but stable multiple.\"},\"bull\":{\"target_price\":196,\"prob\":0.25,\"notes\":\"ZYN and IQOS outperform while deleveraging supports further rerating.\"}},\"method_notes\":\"Blended forward P/E and EV/EBITDA using snapshot fundamentals, anchored to smoke-free growth, margin resilience, leverage, and regulation. Targets exclude dividends; snapshot quote fields remain authoritative. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "OpenAI o3", "risks": [ "Nicotine regulation or flavor restrictions", "Slower IQOS or oral nicotine adoption", "FX volatility across international markets", "Litigation or tax escalation", "Higher rates prolong leverage concerns" ], "ticker": "PM", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Smoke-free growth offsets combustibles and sustains a premium but stable multiple.", "target_price": 173 }, "bear": { "prob": 0.25, "notes": "Growth slows and regulation or FX compresses the valuation multiple.", "target_price": 142 }, "bull": { "prob": 0.25, "notes": "ZYN and IQOS outperform while deleveraging supports further rerating.", "target_price": 196 } }, "confidence": 0.64, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.055, "terminal_multiple": 19.5, "ebit_margin_target": 0.38 }, "key_drivers": [ { "driver": "IQOS adoption", "impact": "HIGH", "direction": "POS" }, { "driver": "Oral nicotine growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Combustible pricing", "impact": "HIGH", "direction": "POS" }, { "driver": "Cigarette volume declines", "impact": "MED", "direction": "NEG" }, { "driver": "Smoke-free margin mix", "impact": "MED", "direction": "POS" }, { "driver": "FX translation", "impact": "MED", "direction": "NEG" }, { "driver": "Debt reduction", "impact": "MED", "direction": "POS" }, { "driver": "Regulation and excise", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Blended forward P/E and EV/EBITDA using snapshot fundamentals, anchored to smoke-free growth, margin resilience, leverage, and regulation. Targets exclude dividends; snapshot quote fields remain authoritative. not investment advice", "current_price": 160.94, "recommendation": "BUY", "thesis_bullets": [ "Smoke-free mix supports above-sector revenue growth and a justified premium multiple.", "IQOS and oral nicotine can offset secular combustible volume declines.", "High margins and cash flow support dividends, buybacks flexibility, and deleveraging.", "Current valuation is full for tobacco, limiting upside if growth normalizes.", "Regulatory, litigation, and currency risks remain material despite defensive demand." ], "target_price_6m": 168.5, "target_price_12m": 173 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_023782a190a63dfc0069d75c801cc48190a2ebf01d956fdd3c", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 37517, "createdAt": "2026-04-09T05:21:36.275Z", "usage": { "inputTokens": 2398, "outputTokens": 2056, "costUsd": 0.032981 } }, { "id": "cmnr14ufr05rwp658aifipui9", "runId": "cmnr14ufp05rsp658ufjjfuly", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"PM DCF Valuation\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"PM\",\n \"currency\": \"USD\",\n \"current_price\": 160.94,\n \"target_price_6m\": 169,\n \"target_price_12m\": 180,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Strong IQOS growth fuels smoke-free revenue\",\n \"Robust pricing power maintains high margins\",\n \"Consistent FCF supports attractive dividend\",\n \"Regulatory risks and volume declines persist\",\n \"Valuation offers modest upside from current levels\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"IQOS adoption rate\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Cigarette volume trends\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Pricing execution\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory changes\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Emerging markets demand\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"FX volatility\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Debt leverage levels\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Competitive intensity\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Stricter global tobacco regulations\",\n \"Ongoing litigation outcomes\",\n \"Slower IQOS market penetration\",\n \"Higher excise taxes\",\n \"Adverse currency shifts\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.06,\n \"ebit_margin_target\": 0.37,\n \"wacc\": 0.085,\n \"terminal_multiple\": 19\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 145,\n \"prob\": 0.3,\n \"notes\": \"Accelerated regulation and volume drops hurt margins.\"\n },\n \"base\": {\n \"target_price\": 180,\n \"prob\": 0.5,\n \"notes\": \"Steady IQOS growth and pricing continue.\"\n },\n \"bull\": {\n \"target_price\": 205,\n \"prob\": 0.2,\n \"notes\": \"Faster smoke-free shift drives re-rating.\"\n }\n },\n \"method_notes\": \"DCF using 6% rev CAGR, 37% EBIT margin, 8.5% WACC and 19x terminal. 12M target implies ~12% upside. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "PM DCF Valuation", "risks": [ "Stricter global tobacco regulations", "Ongoing litigation outcomes", "Slower IQOS market penetration", "Higher excise taxes", "Adverse currency shifts" ], "ticker": "PM", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady IQOS growth and pricing continue.", "target_price": 180 }, "bear": { "prob": 0.3, "notes": "Accelerated regulation and volume drops hurt margins.", "target_price": 145 }, "bull": { "prob": 0.2, "notes": "Faster smoke-free shift drives re-rating.", "target_price": 205 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.06, "terminal_multiple": 19, "ebit_margin_target": 0.37 }, "key_drivers": [ { "driver": "IQOS adoption rate", "impact": "HIGH", "direction": "POS" }, { "driver": "Cigarette volume trends", "impact": "HIGH", "direction": "NEG" }, { "driver": "Pricing execution", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Emerging markets demand", "impact": "MED", "direction": "POS" }, { "driver": "FX volatility", "impact": "MED", "direction": "NEG" }, { "driver": "Debt leverage levels", "impact": "MED", "direction": "NEG" }, { "driver": "Competitive intensity", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF using 6% rev CAGR, 37% EBIT margin, 8.5% WACC and 19x terminal. 12M target implies ~12% upside. not investment advice.", "current_price": 160.94, "recommendation": "BUY", "thesis_bullets": [ "Strong IQOS growth fuels smoke-free revenue", "Robust pricing power maintains high margins", "Consistent FCF supports attractive dividend", "Regulatory risks and volume declines persist", "Valuation offers modest upside from current levels" ], "target_price_6m": 169, "target_price_12m": 180 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "3181c6b6-4ed2-9342-a395-135754b59049", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 15587, "createdAt": "2026-04-09T05:21:36.275Z", "usage": { "inputTokens": 2736, "outputTokens": 3101, "costUsd": 0.054723 } } ] } }